Jiangsu Bioperfectus Technologies Co., Ltd. (688399.SS)
CNY 61.7
(2.15%)
CNY 61.7
(2.15%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 501.3 Million CNY | -54.95% |
| 2022 | 1.11 Billion CNY | 15.57% |
| 2021 | 962.89 Million CNY | 57.03% |
| 2020 | 613.17 Million CNY | 359.06% |
| 2019 | 133.57 Million CNY | 86.91% |
| 2018 | 71.46 Million CNY | 41.88% |
| 2017 | 50.36 Million CNY | 47.74% |
| 2016 | 34.09 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 588.07 Million CNY | 17.31% |
| 2024 Q3 | 569.86 Million CNY | -0.0% |
| 2024 Q2 | 569.86 Million CNY | -3.1% |
| 2023 Q4 | 501.3 Million CNY | -26.62% |
| 2023 FY | 501.3 Million CNY | -54.95% |
| 2023 Q3 | 683.2 Million CNY | 6.9% |
| 2023 Q2 | 639.08 Million CNY | -33.2% |
| 2023 Q1 | 956.71 Million CNY | -14.03% |
| 2022 Q4 | 1.11 Billion CNY | 3.4% |
| 2022 Q3 | 1.07 Billion CNY | -16.79% |
| 2022 Q2 | 1.29 Billion CNY | 4.51% |
| 2022 Q1 | 1.23 Billion CNY | 28.53% |
| 2022 FY | 1.11 Billion CNY | 15.57% |
| 2021 FY | 962.89 Million CNY | 57.03% |
| 2021 Q2 | 548.31 Million CNY | -8.37% |
| 2021 Q1 | 598.37 Million CNY | -2.41% |
| 2021 Q3 | 725.69 Million CNY | 32.35% |
| 2021 Q4 | 962.89 Million CNY | 32.69% |
| 2020 Q3 | 453.97 Million CNY | 42.11% |
| 2020 Q1 | 194.85 Million CNY | 45.88% |
| 2020 FY | 613.17 Million CNY | 359.06% |
| 2020 Q4 | 613.17 Million CNY | 35.07% |
| 2020 Q2 | 319.44 Million CNY | 63.94% |
| 2019 Q3 | 70.96 Million CNY | 11.98% |
| 2019 Q2 | 63.37 Million CNY | 0.0% |
| 2019 Q1 | - CNY | -100.0% |
| 2019 Q4 | 133.57 Million CNY | 88.22% |
| 2019 FY | 133.57 Million CNY | 86.91% |
| 2018 Q4 | 71.46 Million CNY | 0.0% |
| 2018 FY | 71.46 Million CNY | 41.88% |
| 2017 FY | 50.36 Million CNY | 47.74% |
| 2016 FY | 34.09 Million CNY | 0.0% |